

AcouSort Q4 - All eyes forward

Redeye provides an update on AcouSort following its year-end report, which did not include any surprises and was relatively in line with our estimates. Following the report, we make slight revisions to our sales estimates, update our capital injection assumptions, and increase our WACC, resulting in a lowered fair value range.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

AcouSort Q4 - All eyes forward